ライフサイエンスコーパス: methylxanthine

1 sphodiesterase inhibitor, IBMX (3-isobutyl-1-methylxanthine).

2 nolayers treated with forskolin/3-isobutyl-1-methylxanthine.

3 CFTR activation with forskolin/3-isobutyl-1-methylxanthine.

4 taF508 channel activity by 2 mm 3-isobutyl-1-methylxanthine.

5 or specificity change from theophylline to 3-methylxanthine.

6 itors, sildenafil, or zaprinast 3-isobutyl-1-methylxanthine.

7 the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine.

8 g the nonspecific PDE inhibitor 3-isobutyl-1-methylxanthine.

9 rskolin, 1 mmol/l 8-Br-cAMP, or 3-isobutyl-1-methylxanthine.

10 lthio-cAMP, dibutyryl-cAMP, and 3-isobutyl-1-methylxanthine.

11 n kinase A such as forskolin or 3-isobutyl-1-methylxanthine.

12 ntain caffeine, a pharmaceutically important methylxanthine.

13 iction but not glibenclamide or 3-isobutyl-1-methylxanthine.

14 after stimulation by forskolin/3-isobutyl-1-methylxanthine.

15 nitrogen sources but also theophylline and 3-methylxanthine.

16 ere further N demethylated to xanthine via 7-methylxanthine.

17 re is a resurgence of interest in the use of methylxanthines.

18 l cross reactivity with structurally related methylxanthines.

19 the arrest with chemical compounds known as methylxanthines.

20 Fraction 4 was rich in tannins and absent of methylxanthines.

21 ive compounds such as phenolic compounds and methylxanthines.

22 ious studies, placing particular emphasis on methylxanthines.

23 concentrations of CF-derived metabolites and methylxanthines.

24 ia a hitherto unreported pathway to 1- and 3-methylxanthines.

25 cAMP) (forskolin (1-10 microM), 3-isobutyl-1-methylxanthine (0.1-1 mM), rolipram (10 microM), and dib

26 us amounts of cocoa flavanols (0-820 mg) and methylxanthines (0-220 mg), either together or individua

27 ment was assessed by metabolism of infused 1-methylxanthine (1-MX) and by contrast-enhanced ultrasoun

28 protocol 2 subjects, tissue extraction of 1-methylxanthine (1-MX) was measured as an index of perfus

29 as assessed by measuring the metabolism of 1-methylxanthine (1-MX), an exogenously added substrate fo

30 io) (8-CPT)-cAMP (100 micromol/L) + isobutyl methylxanthine (100 micromol/L).

31 ol myristic acid, forskolin and 3-isobutyl-1-methylxanthine, 2) BPDZ 154, or 3) 4-phenylbutyrate.

32 C(50) values for the inhibitors 3-isobutyl-1-methylxanthine (20 microM) and sildenafil (Viagra(TM))(4

33 f forskolin (20 micromol/L) and 3-isobutyl-1-methylxanthine (20 micromol/L), also inhibited GCDC-indu

34 osphodiesterase (PDE) inhibitor 3-isobutyl-1-methylxanthine (20 mumol/L).

35 s-theophylline, theobromine, paraxanthine, 1-methylxanthine, 3-methylxanthine, and 7-methylxanthine-i

36 p RNA linkers to combine theophylline- and 3-methylxanthine (3MX)-binding aptamers with the sgRNA, en

37 the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (5x10(-5) mol/L).

38 hine, and 1-methylxanthine to theobromine, 3-methylxanthine, 7-methylxanthine, and xanthine, respecti

39 t polyphenols, whereas caffeine was the main methylxanthine (90%).

40 zene sulphonate (21 microM) and 3-isobutyl-1-methylxanthine (970 microM, partial inhibition) were als

41 was enhanced in the presence of 3-isobutyl-1-methylxanthine, a cAMP phosphodiesterase inhibitor.

42 ydig cells from wild-type mice, 3-isobutyl-1-methylxanthine, a compound that inhibits all cAMP PDEs e

43 has been proposed that caffeine and related methylxanthines activate taste-receptor cells through in

44 newborns respond adequately to, or tolerate, methylxanthine administration, and thus alternative phar

45 should explore optimal dosing and timing of methylxanthine administration.

46 Oral or intravenous methylxanthine agents may be given for more severe PDPH.

47 activating CFTR with forskolin/3-isobutyl-1-methylxanthine alkalinized NL ASL but acidified CF ASL;

48 monophospate sodium), and IBMX (3-isobutyl-1-methylxanthine) also changed the splicing pattern.

49 In the presence of Mg(2+), methylxanthines altered the structure of DNA from B to A

50 ed by 2',5'-dideoxyadenosine or 3-isobutyl-1-methylxanthine, an inhibitor of phosphodiesterase.

51 1-Methylxanthine and 3-methylxanthine were subsequently N

52 of matched doses (300 nmol) of 3-isobutyl-1-methylxanthine and 7-deacetyl-7-O-(N-methylpiperazino)-g

53 y by the nonselective PDE inhibitor isobutyl methylxanthine and also by the selective PDE 3B inhibito

54 ese effects were potentiated by 3-isobutyl-1-methylxanthine and attenuated by the adenylyl cyclase in

55 intracellular cAMP prompted by 3-isobutyl-1-methylxanthine and forskolin partially mimicked the effe

56 However, 3-isobutyl-1-methylxanthine and forskolin treatment of a muscle that

57 GSIS), and insulin secretion to 3-isobutyl-1-methylxanthine and KCl were all reduced without altering

58 ex with non-selective inhibitor 3-isobutyl-1-methylxanthine and kinetic analysis on the mutants of PD

59 ch associations were partially mediated by 1-methylxanthine and nicotinate (variance accounted for me

60 d) complexed with sildenafil or 3-isobutyl-1-methylxanthine and the Pgamma-inhibitory peptide Pgamma(

61 ted by dibutyryl cyclic-cAMP or 3-isobutyl-1-methylxanthine and the somatostatin (SST) receptor 2-5 a

62 microM forskolin and 300 microM 3-isobutyl-L-methylxanthine and voltage-clamped with pipettes contain

63 Release was also stimulated by 3-isobutyl-1-methylxanthine and was additive with forskolin.

64 rdenafil or sildenafil (but not 3-isobutyl-1-methylxanthine and zaprinast) induced a distinct conform

65 icrobiological characteristics and levels of methylxanthines and bioactive amines of cocoa.

66 extraction methods for the determination of methylxanthines and tannins were investigated.

67 al outcomes in 52 infants with HIE receiving methylxanthines and therapeutic hypothermia.

68 xtract 1 obtained good yields of tannins and methylxanthines and was used to identify a type-A procya

69 eobromine, paraxanthine, 1-methylxanthine, 3-methylxanthine, and 7-methylxanthine-in their respective

70 Forskolin, 3-isobutyl-1-methylxanthine, and 8-bromo-cAMP (8-Br-cAMP) increased [

71 (MEF-KO) impairs dexamethasone, 3-isobutyl-1-methylxanthine, and insulin (DMI)-induced adipocyte diff

72 se [cAMP] (forskolin, rolipram, 3-isobutyl-1-methylxanthine, and papaverine) or mimic cAMP (8-bromo-c

73 d was mimicked by 8-bromo-cAMP, 3-isobutyl-1-methylxanthine, and Sp-cAMP.

74 he phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine, and the adenylate cyclase activator, for

75 xanthine to theobromine, 3-methylxanthine, 7-methylxanthine, and xanthine, respectively.

76 R2 by the same mechanism as phosphorylation, methylxanthines, and mutations, via changes in the thres

77 ration of adenosine antagonists, such as the methylxanthines antagonists caffeine and theophylline, o

78 ed mTOR in vitro, demonstrating that certain methylxanthines are able to inhibit mTOR independently o

79 the 8'-methyl carbinols of these N7-methyl-8-methylxanthines are formed in substantial amounts with e

80 By contrast, the N7-methyl-8-methylxanthines are good substrates for CYP1A2 but are n

81 Catechins and methylxanthines are natural molecules in guarana (Paulli

82 ntally friendly enzymatic reaction products, methylxanthines, are high-value biochemicals that are us

83 y caffeine, theobromine, paraxanthine, and 7-methylxanthine as sole carbon and nitrogen sources but a

84 Vpr-mediated G2 arrest was alleviated by methylxanthines at concentrations similar to those neede

85 asma, SSBs were positively associated with 1-methylxanthine (beta: 0.0005; 95% CI: 0.0003, 0.0008; an

86 teins, carbohydrates, vitamins, polyphenols, methylxanthines, bioactive amines, and aromas.

87 levels of the mood pyramid model (flavanols, methylxanthines, biogenic amines and orosensory properti

88 2 [(E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methylxanthine], both in normal and in dopamine-depleted

89 t beneficial: 16,607 (24%) were treated with methylxanthine bronchodilators, 10,051 (14%) had sputum

90 d replacement, oxygen, glucocorticosteroids, methylxanthines, bronchodilators, management plans, food

91 include flavan-3-ols, proanthocyanidins and methylxanthines, but also biogenic amines and alkaloids.

92 We have previously reported that the methylxanthine caffeine increases expression of the spli

93 In both types of organisms, the methylxanthine caffeine overrides the synthesis (S)-M ch

94 ffeic, ferulic and p-coumaric acids) and two methylxanthines (caffeine, theobromine) were studied, ac

95 and Mexican Northwest reveal combinations of methylxanthines (caffeine, theobromine, and theophylline

96 talyzed N(3)-demethylation of theobromine, 3-methylxanthine, caffeine, and theophylline to 7-methylxa

97 Derivatives of methylxanthine can potentially induce harmful impacts on

98 were no differences in circulating levels of methylxanthines, catecholamines, or glucose.

99 10 microm forskolin, 40 microm 3-isobutyl-1-methylxanthine caused a 50% reduction in myosin II regul

100 the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine, caused a rightward shift in the current-

101 ructures together with the PDE5A1-isobutyl-1-methylxanthine complex show that the H-loop (residues 66

102 er shows less heterogeneity in the aptamer-3-methylxanthine complex than what is observed in the theo

103 y structure of DNA remained unaltered in DNA-methylxanthines complexes or in the absence of Mg(2+).

104 ferent brewing methods on the polyphenol and methylxanthine composition and antioxidant capacity of t

105 ave highlighted its rich polyphenol content, methylxanthine composition, and antioxidant properties,

106 mportant source of polyphenols with moderate methylxanthines content; therefore its high antioxidant

107 ures reveal how substituent positions on the methylxanthine core dictate binding modes and inducible-

108 of methyl group substitutions on the 1- or 3-methylxanthine core structure.

109 ot to act on the cyclase, or by 3-isobutyl-1-methylxanthine, creatine phosphate, or creatine kinase.

110 esent study demonstrates that theobromine, a methylxanthine derivative present in cocoa, effectively

111 l library screening to identify and optimize methylxanthine derivatives as selective bioavailable PAR

112 under identical culture conditions (isobutyl-methylxanthine, dexamethasone, and insulin), revealed mu

113 n tyrosinase activity by either 3-isobutyl-1-methylxanthine, dibutyryl cAMP, or forskolin.

114 ets perifused with glucose and 3-isobutryl-1-methylxanthine did not respond to glucose deprivation by

115 ombination of dexamethasone and 3-isobutyl-1-methylxanthine (DM) is suppressed by 2,3,7,8 tetrachloro

116 gnalling and is transcriptionally induced by methylxanthine drugs such as caffeine and theophylline,

117 howed 24-35% of enhanced binding activity of methylxanthines during helix-coil transitions of DNA rat

118 l ester hydrochloride (T-0156), 3-isobutyl-1-methylxanthine, EDTA, or cGMP, but not by cAMP or 5'-GMP

119 tial interaction between cocoa flavanols and methylxanthines exists at the level of absorption, in wh

120 r an interaction between cocoa flavanols and methylxanthines exists that influences cocoa flavanol-de

121 Clinical trials of methylxanthines for neuroprotection in HIE are needed to

122 response of other ORNs to IBMX (3-isobutyl-1-methylxanthine)/forskolin in a PI3K-dependent manner arg

123 e potential of extracts and tannins-rich and methylxanthines-free fraction from guarana in the anti-i

124 ytochrome P450 1A2) activity caused by the 8-methylxanthine furafylline is investigated with the aim

125 However, 3-methylxanthine-grown CBB5 cells did not metabolize caffe

126 Theobromine-, paraxanthine-, and 7-methylxanthine-grown cells also metabolized all of the m

127 lin, 1 mM 8-bromo-cAMP, or 1 mM 3-isobutyl-1-methylxanthine) had no effect on the amplitude of Kv1.5

128 with the nonselective inhibitor 3-isobutyl-1-methylxanthine have been determined at medium resolution

129 We have examined the effects of 1-isobutyl-3-methylxanthine (IBMX) and forskolin, agonists that eleva

130 tal structure as a complex with 3-isobutyl-1-methylxanthine (IBMX) at 1.55 A resolution.

131 The nonselective inhibitor 3-isobutyl-1-methylxanthine (IBMX) binds to a similar subpocket in th

132 tructures in the unliganded and 3-isobutyl-1-methylxanthine (IBMX) bound forms at 1.9 and 2.1 A resol

133 osphodiesterase (PDE) inhibitor 3-isobutyl-1-methylxanthine (IBMX) did not elevate cGMP on its own bu

134 y treated with forskolin and/or 3-isobutyl-1-methylxanthine (IBMX) in light-dark (LD) and DD.

135 ective phosphodiesterase inhibitor, isobutyl methylxanthine (IBMX) increased the potency of PACAP at

136 ion and the increased effect of 3-isobutyl-1-methylxanthine (IBMX) observed in GADA+ donor islets.CON

137 3-Isobutyl-1-methylxanthine (IBMX) or 8-bromoadenosine 3',5'-cyclic m

138 MP levels with either forskolin/3-isobutyl-1-methylxanthine (IBMX) or the V2 receptor agonist [deamin

139 P, carbachol, forskolin, and/or 3-isobutyl-1-methylxanthine (IBMX) to determine whether these agents,

140 afil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 12

141 In the presence of 3-isobutyl-1-methylxanthine (IBMX), 10 microM SNC was sufficient to i

142 3-Isobutyl-1-methylxanthine (IBMX), a non-specific phosphodiesterase

143 Moreover, 3-isobutyl-1-methylxanthine (IBMX), an inhibitor of cAMP phosphodiest

144 10 mmol/l arginine, 0.1 mmol/l 3-isobutyl-1-methylxanthine (IBMX), and 5 micromol/l carbachol induce

145 ells to cAMP-increasing agents, 3-isobutyl-1-methylxanthine (IBMX), and forskolin completely abolishe

146 A nonselective PDE inhibitor, 3-isobutyl-1-methylxanthine (IBMX), and the PDE3 selective inhibitors

147 the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX), decreased the period (increased t

148 the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX), the circulating current was resto

149 sed by the use of forskolin and 3-isobutyl-1-methylxanthine (IBMX), we show that increase of cAMP res

150 t transfections, forskolin plus 3-isobutyl-1-methylxanthine (IBMX), which increases intracellular cAM

151 s, leading to stable, forskolin+3-isobutyl-1-methylxanthine (IBMX)-activated whole-cell currents in t

152 MP, vardenafil, sildenafil, and 3-isobutyl-1-methylxanthine (IBMX).

153 he phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine (IBMX).

154 the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX).

155 lation with forskolin (FSK) and 3-isobutyl-1-methylxanthine (IBMX).

156 ent with an adipogenic inducer, 3-isobutyl-1-methylxanthine (IBMX).

157 the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX, 750 microM) reversibly increased t

158 Incubating cells with PDGF and 3-isobutyl-1-methylxanthine (IBMX, a phosphodiesterase inhibitor) enh

159 n succinate-, ketoisocaproate-, 3-isobutyl-1-methylxanthine (IBMX-), KCl-, and tolbutamide-induced in

160 mol/L; >3-fold), potentiated by 3-isobutyl-1-methylxanthine (IBMX; phosphodiesterase type 5 inhibitor

161 ase (cAMP-PDE) inhibitors, e.g. 3-isobutyl-1-methylxanthine [(IBMX) or caffeine, 10 mg/kg] or the mor

162 tentials upon presentation of theobromine, a methylxanthine in cocoa.

163 sustained response to glucose plus isobutyl-methylxanthine in perifusion studies that is clearly lar

164 the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine in proportion to increases in intracellul

165 ed, as was the response to theophylline, the methylxanthine in tea.

166 the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine in the medium, suggesting extracellular c

167 A fast method for the determination of methylxanthines in cocoa products and drugs based on PS-

168 for the determination of phenolic acids and methylxanthines in tea (Camellia Sinensis) samples.

169 However, data on the safety and efficacy of methylxanthines in the setting of therapeutic hypothermi

170 e, 1-methylxanthine, 3-methylxanthine, and 7-methylxanthine-in their respective protonated ions using

171 3-isobutyl-1-methylxanthine increased insulin secretion but had littl

172 phosphodiesterase activity with 3-isobutyl-1-methylxanthine, indicating that alpha-adrenergic stimula

173 we have investigated the mechanisms by which methylxanthines induce this aberrant overexpression.

174 he broad-spectrum PDE inhibitor 3-isobutyl-1-methylxanthine induced T cell CREB phosphorylation, we t

175 tors for their ability to mimic 3-isobutyl-1-methylxanthine-induced ATF-1/CREB phosphorylation.

176 The receptor inhibitor 3-isobutyl-1-methylxanthine inhibited the calcium response to adenosi

177 Methylxanthine intake alone did not result in statistica

178 pathways converged at xanthine via different methylxanthine intermediates.

179 ity was measured with the IBMX (3-isobutyl-1-methylxanthine) jump technique.

180 s were randomized to receive the substituted methylxanthine, lisofylline (CT1501R), or an identically

181 sts at the level of absorption, in which the methylxanthines mediate an increased plasma concentratio

182 g treatment with these diols or 3-isobutyl-1-methylxanthine, melanin and tyrosinase activity are incr

183 hine-grown cells also metabolized all of the methylxanthines mentioned above via the same pathway.

184 cept, consists of four levels (flavan-3-ols, methylxanthines, minor compounds and orosensory properti

185 Rgamma) by dexamethasone (DEX), 3-isobutyl-1-methylxanthine (MIX), and insulin.

186 eviously attributed to one broad-specificity methylxanthine N-demethylase composed of two subunits, N

187 individual catechins, methylxanthines) of tea shoots (Camellia sinensis).

188 th forskolin, 8-bromo-cAMP, and 3-isobutyl-1-methylxanthine or by overexpression of the catalytic sub

189 ucing novel products increasing polyphenols, methylxanthines or dietary fibre to improve purported he

190 ocoa had higher levels of monomeric phenols, methylxanthines, phenylethylamine and lower levels of th

191 3-Isobutyl-1-methylxanthine potentiated ATP-induced calcium transient

192 n inability to avoid caffeine or the related methylxanthine present in tea, theophylline.

193 Caffeine is a methylxanthine present in the coffee tree, tea plant, an

194 ith 8-bromo cAMP, forskolin, or 3-isobutyl-1-methylxanthine prevented the CD47-mediated apoptosis, an

195 Methylxanthines reduced extubation failure (RR, 0.48; 95

196 ethylxanthine, xanthine, paraxanthine, and 1-methylxanthine, respectively.

197 8.6 mg of total-dietary-fibre, flavanols and methylxanthines, respectively) as well as PPCP (providin

198 9.8 mg of total-dietary-fibre, flavanols and methylxanthines, respectively) on cardiovascular health

199 ake, the consumption of cocoa flavanols with methylxanthines resulted in a greater enhancement of FMD

200 tein kinase (PKA), MgATP, cGMP, 3-isobutyl-1-methylxanthine], shown earlier to produce Ser92 phosphor

201 ucts had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, bu

202 Caffeine, a methylxanthine, slightly increased basal levels of cAMP,

203 The forskolin/3-isobutyl-1-methylxanthine-stimulated whole-cell conductance in hCFT

204 udied the interaction of naturally occurring methylxanthines such as theophylline, theobromine and ca

205 Methylxanthines, such as caffeine and aminophylline, hav

206 aptamer that binds with higher affinity to 3-methylxanthine than theophylline.

207 fter the co-ingestion of cocoa flavanols and methylxanthines than after the intake of cocoa flavanols

208 e obtained when pure (-)-epicatechin and the methylxanthines theobromine and caffeine were consumed t

209 However, cocoa also contains the methylxanthines theobromine and caffeine, which may also

210 Flavan-3-ols (catechin, epicatechin), methylxanthines (theobromine, caffeine), total phenolic

211 caffeine, theophylline, paraxanthine, and 1-methylxanthine to theobromine, 3-methylxanthine, 7-methy

212 dent Rieske oxygenase for demethylation of 7-methylxanthine to xanthine, the final step in caffeine N

213 CBB5 also oxidized theophylline and 1- and 3-methylxanthines to 1,3-dimethyluric acid and 1- and 3-me

214 histamines, systemic glucocorticosteroids or methylxanthines to manage anaphylaxis.

215 alkaloids, metabolizes caffeine and related methylxanthines via sequential N-demethylation to xanthi

216 ndent conversion of theophylline to 1- and 3-methylxanthines was also detected in the crude cell extr

217 The highest level of catechins and methylxanthines was extracted with HHM.

218 cGMP, and IC50 for zaprinast or 3-isobutyl-1-methylxanthine were found among wild-type and mutant cGB

219 1-Methylxanthine and 3-methylxanthine were subsequently N demethylated to xanth

220 was more pronounced when cocoa flavanols and methylxanthines were ingested together.

221 Polyphenols and methylxanthines were qualitatively and quantitatively an

222 Additionally, 46 polyphenols and 2 methylxanthines were quantified by HPLC-DAD.

223 is an enantiomer-specific, alkyl-substituted methylxanthine, which has specific and potent activity i

224 ons for myopia are limited to atropine and 7-methylxanthine, which have either significant adverse ef

225 mbination of dibutyryl cAMP and 3-isobutyl-1-methylxanthine, which increase intracellular Ca2+ and cA

226 3-isobutyl-1-methylxanthine, which potentiates the cGMP/cAMP-signalin

227 t is most potently inhibited by 3-isobutyl-1-methylxanthine with an IC(50) of 2.1 microM.

228 hylxanthine, caffeine, and theophylline to 7-methylxanthine, xanthine, paraxanthine, and 1-methylxant

229 by ANP/BNP, or blocking PDE by 3-isobutyl-1-methylxanthine/zaprinast caused significant inhibition o